Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | proto oncogene serine:threonine protein kinase | 0.2519 | 1 | 1 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.1074 | 0.3729 | 0.5 |
Loa Loa (eye worm) | CAMK/CAMKL/PASK protein kinase | 0.1894 | 0.7286 | 0.5672 |
Brugia malayi | Serine/threonine-protein kinase Pim-3 | 0.2519 | 1 | 1 |
Echinococcus multilocularis | proto oncogene serine:threonine protein kinase | 0.2519 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1074 | 0.3729 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1074 | 0.3729 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1074 | 0.3729 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1074 | 0.3729 | 0.5 |
Trypanosoma brucei | Casein kinase II | 0.1074 | 0.3729 | 1 |
Trypanosoma cruzi | casein kinase II, putative | 0.1074 | 0.3729 | 0.5 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.2519 | 1 | 1 |
Leishmania major | casein kinase II, putative | 0.1074 | 0.3729 | 0.5 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.2519 | 1 | 1 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.1074 | 0.3729 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.1074 | 0.3729 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1074 | 0.3729 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1074 | 0.3729 | 0.5 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.1074 | 0.3729 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1074 | 0.3729 | 0.5 |
Onchocerca volvulus | Serine\/threonine protein kinase homolog | 0.2519 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CK2 | 0.1074 | 0.3729 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.2519 | 1 | 1 |
Plasmodium vivax | unspecified product | 0.1074 | 0.3729 | 0.5 |
Entamoeba histolytica | casein kinase, putative | 0.1074 | 0.3729 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.